메뉴 건너뛰기




Volumn 39, Issue 4, 2004, Pages 388-393

The effectiveness and safety of botulinum toxin in the treatment of chronic primary headaches;Eficacia y seguridad del tratamiento con toxina botulínica en las cefaleas primarias crónicas

Author keywords

Botulinum toxin; Chronic migraine; Daily chronic headache; Headache prophylaxis; Neuromodulation

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CYANOCOBALAMIN; CYPROHEPTADINE; FLUOXETINE; GABAPENTIN; MAGNESIUM; METOPROLOL; NEUROPEPTIDE; NORTRIPTYLINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; VERAPAMIL;

EID: 4744355580     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3904.2003548     Document Type: Review
Times cited : (1)

References (65)
  • 1
    • 0034925369 scopus 로고    scopus 로고
    • Clinical evaluation of a patient presenting with headache
    • Purdy RA. Clinical evaluation of a patient presenting with headache. Med Clin North Am 2001; 85: 847-63.
    • (2001) Med Clin North Am , vol.85 , pp. 847-863
    • Purdy, R.A.1
  • 2
    • 0034913120 scopus 로고    scopus 로고
    • Evaluation and management of headache in the emergency room
    • Ward TN, Levin M, Phillips JM. Evaluation and management of headache in the emergency room. Med Clin North Am 2001; 85: 971-86.
    • (2001) Med Clin North Am , vol.85 , pp. 971-986
    • Ward, T.N.1    Levin, M.2    Phillips, J.M.3
  • 4
    • 0026728886 scopus 로고
    • Undiagnosed migraine headaches: A comparison of symptom-based and reported physician diagnosis
    • Lipton RB, Stewart WF, Celenrano DD, Reed ML. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992; 152: 1273-8.
    • (1992) Arch Intern Med , vol.152 , pp. 1273-1278
    • Lipton, R.B.1    Stewart, W.F.2    Celenrano, D.D.3    Reed, M.L.4
  • 5
    • 0034883732 scopus 로고    scopus 로고
    • Prevalence and burden of migraine in the United States: Data from the American migraine study II
    • Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001; 41: 64-7.
    • (2001) Headache , vol.41 , pp. 64-67
    • Lipton, R.B.1    Stewart, W.F.2    Diamond, S.3    Diamond, M.L.4    Reed, M.5
  • 6
    • 0034826748 scopus 로고    scopus 로고
    • Migraña: Implicaciones laborales, discapacidad y solicitud de servicios de salud en Colombia
    • Aicardi E, Reynales H, Valencia D. Migraña: Implicaciones laborales, discapacidad y solicitud de servicios de salud en Colombia. Rev Neurol 2001; 32: 1001-5.
    • (2001) Rev Neurol , vol.32 , pp. 1001-1005
    • Aicardi, E.1    Reynales, H.2    Valencia, D.3
  • 9
    • 0034887548 scopus 로고    scopus 로고
    • Migraine diagnosis and treatment: Results from the American Migraine Study II
    • Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638-45.
    • (2001) Headache , vol.41 , pp. 638-645
    • Lipton, R.B.1    Diamond, S.2    Reed, M.3    Diamond, M.L.4    Stewart, W.F.5
  • 11
    • 0034626361 scopus 로고    scopus 로고
    • The diagnostic value of historical features in primary headache syndromes
    • Smetana GW. The diagnostic value of historical features in primary headache syndromes. Arch Intem Med 2000; 160: 2729-37.
    • (2000) Arch Intem Med , vol.160 , pp. 2729-2737
    • Smetana, G.W.1
  • 12
    • 0034945368 scopus 로고    scopus 로고
    • Diagnosis of migraine, empirical analysis of a large clinical simple of atypical migraine (IHS 1.7) patients and proposed revision of the IHS criteria
    • Rains JC, Penzien DB, Lipchick GL, Ramadan NM. Diagnosis of migraine, empirical analysis of a large clinical simple of atypical migraine (IHS 1.7) patients and proposed revision of the IHS criteria. Cephalalgia 2001; 21: 583-95.
    • (2001) Cephalalgia , vol.21 , pp. 583-595
    • Rains, J.C.1    Penzien, D.B.2    Lipchick, G.L.3    Ramadan, N.M.4
  • 13
    • 0037076421 scopus 로고    scopus 로고
    • The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine
    • Diamond ML. The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine. Neurology 2002; 58 (Suppl 6): S3-9.
    • (2002) Neurology , vol.58 , Issue.SUPPL. 6
    • Diamond, M.L.1
  • 14
    • 0037076362 scopus 로고    scopus 로고
    • Sinus headache or migraine? Considerations in making a differential diagnosis
    • Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 2002; 58 (Suppl 6): S10-4.
    • (2002) Neurology , vol.58 , Issue.SUPPL. 6
    • Cady, R.K.1    Schreiber, C.P.2
  • 15
    • 0037076422 scopus 로고    scopus 로고
    • Migraine and tension-type headache: An assessment of challenges in diagnosis
    • Kaniecki RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neurology 2002; 58 (Suppl 6): S15-20.
    • (2002) Neurology , vol.58 , Issue.SUPPL. 6
    • Kaniecki, R.G.1
  • 16
    • 0037345762 scopus 로고    scopus 로고
    • Migraine preventive medication reduces resource utilization
    • Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003; 43: 171-8.
    • (2003) Headache , vol.43 , pp. 171-178
    • Silberstein, S.D.1    Winner, P.K.2    Chmiel, J.J.3
  • 17
    • 0036616193 scopus 로고    scopus 로고
    • The economic impact of migraine: An analysis of direct and indirect costs
    • Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002; 42: 501-9.
    • (2002) Headache , vol.42 , pp. 501-509
    • Edmeads, J.1    Mackell, J.A.2
  • 19
    • 1442265540 scopus 로고    scopus 로고
    • The International Classification of Headache Disorders
    • Headache Subcommittee of the International Headache Society
    • The International Classification of Headache Disorders. Headache Subcommittee of the International Headache Society. Cephalalgia 2004; 24 (Suppl 1): 1-150.
    • (2004) Cephalalgia , vol.24 , Issue.SUPPL. 1 , pp. 1-150
  • 20
    • 0344267641 scopus 로고    scopus 로고
    • Epidemiology of chronic daily headache in the general population
    • Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-6.
    • (1999) Headache , vol.39 , pp. 190-196
    • Castillo, J.1    Muñoz, P.2    Guitera, V.3    Pascual, J.4
  • 22
    • 0001694653 scopus 로고    scopus 로고
    • Migraine: Diagnosis and treatment
    • Silberstein SD, Lipton RB, Dalessio DJ, eds. New York: Oxford University Press
    • Silberstein SL, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and other head pain. 7 ed. New York: Oxford University Press; 2001. p. 121-237.
    • (2001) Wolff's Headache and Other Head Pain. 7 Ed. , pp. 121-237
    • Silberstein, S.L.1    Saper, J.R.2    Freitag, F.G.3
  • 24
    • 0043245854 scopus 로고    scopus 로고
    • Pharmacological approaches to migraine
    • Diener HCH. Pharmacological approaches to migraine. J Neural Transin 2003 (Suppl); 64: 35-63.
    • (2003) J Neural Transin , vol.64 , Issue.SUPPL. , pp. 35-63
    • Diener, H.C.H.1
  • 25
    • 1442359548 scopus 로고    scopus 로고
    • Topiramate for migraine prevention: A randomized controlled trial
    • Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al, MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-73.
    • (2004) JAMA , vol.291 , pp. 965-973
    • Brandes, J.L.1    Saper, J.R.2    Diamond, M.3    Couch, J.R.4    Lewis, D.W.5    Schmitt, J.6
  • 26
    • 2342461018 scopus 로고    scopus 로고
    • Topiramate in migraine prevention: Results of a large controlled trial
    • Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
    • (2004) Arch Neurol , vol.61 , pp. 490-495
    • Silberstein, S.D.1    Neto, W.2    Schmitt, J.3    Jacobs, D.4
  • 28
    • 0037540062 scopus 로고    scopus 로고
    • Preventive treatment for migraine and tension-type headaches. Do drugs heaving effects on muscle spasm and tone have a role?
    • Freitag FG. Preventive treatment for migraine and tension-type headaches. Do drugs heaving effects on muscle spasm and tone have a role? CNS Drugs 2003; 17: 373-81.
    • (2003) CNS Drugs , vol.17 , pp. 373-381
    • Freitag, F.G.1
  • 29
    • 0346074482 scopus 로고    scopus 로고
    • Long-term use of botulinum toxin type A (Botox) in the treatment of episodic and chronic migraine headaches
    • Mauskop A. Long-term use of botulinum toxin type A (Botox) in the treatment of episodic and chronic migraine headaches. Neurology 2002; 58 (Suppl 3): A497.
    • (2002) Neurology , vol.58 , Issue.SUPPL. 3
    • Mauskop, A.1
  • 30
    • 0037874443 scopus 로고    scopus 로고
    • Botulinum toxin type A (Botox) therapy for intractable headache
    • Troost BT. Botulinum toxin type A (Botox) therapy for intractable headache. Headache 2002; 42: 435.
    • (2002) Headache , vol.42 , pp. 435
    • Troost, B.T.1
  • 31
    • 0036840845 scopus 로고    scopus 로고
    • Use of botulinum toxins for chronic headaches: A focused review
    • Loder E, Biondi D. Use of botulinum toxins for chronic headaches: a focused review. Clin J Pain 2002; 18 (Suppl 6): S169-76.
    • (2002) Clin J Pain , vol.18 , Issue.SUPPL. 6
    • Loder, E.1    Biondi, D.2
  • 32
    • 4744344348 scopus 로고    scopus 로고
    • Botulinum toxin type A in the preventive treatment of refractory headaches-comparison between medication overuse and nonmedication overusers groups
    • Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM. Botulinum toxin type A in the preventive treatment of refractory headaches-comparison between medication overuse and nonmedication overusers groups [poster]. Cephalalgia 2003; 23: 715.
    • (2003) Cephalalgia , vol.23 , pp. 715
    • Tepper, S.J.1    Bigal, M.E.2    Sheftell, F.D.3    Rapoport, A.M.4
  • 33
    • 0036692121 scopus 로고    scopus 로고
    • The use of botulinum toxin in the treatment of headaches
    • Mauskop A. The use of botulinum toxin in the treatment of headaches. Curr Pain Headache Rep 2002; 6: 320-3.
    • (2002) Curr Pain Headache Rep , vol.6 , pp. 320-323
    • Mauskop, A.1
  • 34
    • 38849161313 scopus 로고    scopus 로고
    • Toxina botulínica: Origen, estructura, actividad, farmacología y cinética
    • López del Val LJ, Castro A, eds. Barcelona: Masson
    • Bartolomé MR, Lazuna FJ. Toxina botulínica: origen, estructura, actividad, farmacología y cinética. In López del Val LJ, Castro A, eds. Toxina botulínica: aplicaciones terapéuticas. Barcelona: Masson; 2002. p. 3-22.
    • (2002) Toxina Botulínica: Aplicaciones Terapéuticas , pp. 3-22
    • Bartolomé, M.R.1    Lazuna, F.J.2
  • 35
    • 0042710491 scopus 로고    scopus 로고
    • Immunologic and other properties of therapeutic botulinum toxin serotypes
    • Brin MF, Hallet M, Jankovic J, eds. Philadelphia: Lippincott Williams and Wilkins
    • Aoki KR. Immunologic and other properties of therapeutic botulinum. toxin serotypes. In Brin MF, Hallet M, Jankovic J, eds. Scientific therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 103-14.
    • (2002) Scientific Therapeutic Aspects of Botulinum Toxin , pp. 103-114
    • Aoki, K.R.1
  • 36
    • 0037396608 scopus 로고    scopus 로고
    • Dynamics of motor nerve terminal remodelling unveiled using SNARE-cleaving toxins: The extent and duration are dictated by the sites of SNAP-25 truncation
    • Meunier FA, Lisk G, Sesardie D, Dolly JO. Dynamics of motor nerve terminal remodelling unveiled using SNARE-cleaving toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurobiol 2003; 22: 454-66.
    • (2003) Mol Cell Neurobiol , vol.22 , pp. 454-466
    • Meunier, F.A.1    Lisk, G.2    Sesardie, D.3    Dolly, J.O.4
  • 37
    • 4644369057 scopus 로고    scopus 로고
    • Spread of paralysis to nearby and distant noninjected muscles in a monkey hand model: Comparison of BoNT-B and BoNT-A
    • Brin MF, Hallet M, Jankovic J, eds. Philadelphia: Lippincott Williams and Wilkins
    • Arezzo JC, Mona S, Litwak MS, Caputo FA, Meyer KE, Shopp GM. Spread of paralysis to nearby and distant noninjected muscles in a monkey hand model: comparison of BoNT-B and BoNT-A. In Brin MF, Hallet M, Jankovic J, eds. Scientific therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 123-34.
    • (2002) Scientific Therapeutic Aspects of Botulinum Toxin , pp. 123-134
    • Arezzo, J.C.1    Mona, S.2    Litwak, M.S.3    Caputo, F.A.4    Meyer, K.E.5    Shopp, G.M.6
  • 38
    • 0033917504 scopus 로고    scopus 로고
    • Botulinum toxin type A as a migraine preventive treatment
    • Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445-50.
    • (2000) Headache , vol.40 , pp. 445-450
    • Silberstein, S.1    Mathew, N.2    Saper, J.3    Jenkins, S.4
  • 39
    • 0033668492 scopus 로고    scopus 로고
    • Botulinum toxin type A (Botox) for the treatment of migraine headaches: An open label study
    • Binder WJ. Botulinum toxin type A (Botox) for the treatment of migraine headaches: an open label study. Otolaryngol Head Neck Surg 2000; 123: 669-76.
    • (2000) Otolaryngol Head Neck Surg , vol.123 , pp. 669-676
    • Binder, W.J.1
  • 40
    • 4744374371 scopus 로고    scopus 로고
    • Efficacy and safety of botulinum toxin type A (Botox) in the prophylactic treatment of migraine
    • Seattle
    • Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A (Botox) in the prophylactic treatment of migraine. 44th Annual Scientific American Headache Society Meeting. Seattle; 2002. p. S106.
    • (2002) 44th Annual Scientific American Headache Society Meeting
    • Barrientos, N.1    Chana, P.2
  • 41
    • 0043234545 scopus 로고    scopus 로고
    • Botulinum neurotoxin for the treatment of migraine and other primar headache disorders: From bench to bedside
    • Dodick D. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003; 43 (Suppl 1): S25-33.
    • (2003) Headache , vol.43 , Issue.SUPPL. 1
    • Dodick, D.1
  • 42
    • 0042369054 scopus 로고    scopus 로고
    • The use of botulinum toxin type A in headache treatment
    • Mathew NT, Kaup AO. The use of botulinum toxin type A in headache treatment. Curr Treat Opin Neurol 2002; 4: 365-73.
    • (2002) Curr Treat Opin Neurol , vol.4 , pp. 365-373
    • Mathew, N.T.1    Kaup, A.O.2
  • 43
    • 0034758711 scopus 로고    scopus 로고
    • Review of botulinum toxin type A and its clinical applications in migraine headache
    • Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2001; 2: 1649-54.
    • (2001) Expert Opin Pharmacother , vol.2 , pp. 1649-1654
    • Silberstein, S.D.1
  • 44
    • 0002661469 scopus 로고    scopus 로고
    • Botox for migraine: Double-blind, placebo-controlled, region-specific evaluation
    • Brin MF, Swope DM, O'Brian C, Abbasi S, Pogoda JM. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia 2000; 20: 421-2.
    • (2000) Cephalalgia , vol.20 , pp. 421-422
    • Brin, M.F.1    Swope, D.M.2    O'Brian, C.3    Abbasi, S.4    Pogoda, J.M.5
  • 45
    • 4744345565 scopus 로고    scopus 로고
    • Survey expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment
    • Olensen J, Silberstein SD, Tfelt-Hansen P, eds. New York: Oxford University Press
    • Coloprisco G, De Filippis S, Santi PG, Fiore G, Rodio A, Martelleti P. Survey expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment. In Olensen J, Silberstein SD, Tfelt-Hansen P, eds. Preventive pharmacotherapy of headaches disorders. Frontiers in headache research. New York: Oxford University Press; 2004. p. 163-7.
    • (2004) Preventive Pharmacotherapy of Headaches Disorders. Frontiers in Headache Research , pp. 163-167
    • Coloprisco, G.1    De Filippis, S.2    Santi, P.G.3    Fiore, G.4    Rodio, A.5    Martelleti, P.6
  • 46
    • 0346094042 scopus 로고    scopus 로고
    • Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients
    • Schim J. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Curr Med Res Opin 2004; 20: 49-53.
    • (2004) Curr Med Res Opin , vol.20 , pp. 49-53
    • Schim, J.1
  • 47
    • 4744345564 scopus 로고    scopus 로고
    • Botulinum toxin A in the prophylaxis of migraine: A double-blind, placebo-controlled, randomized study comparing frontal and cervical injection
    • Olensen J, Silberstein SD, Tfelt-Hansen P, eds. New York: Oxford University Press
    • Schwaag S, Rahmann A, Frese A, Husstedt I-W, Vollmer-Haase J, Evers S. Botulinum toxin A in the prophylaxis of migraine: a double-blind, placebo-controlled, randomized study comparing frontal and cervical injection. In Olensen J, Silberstein SD, Tfelt-Hansen P, eds. Preventive pharmacotherapy of headaches disorders. Frontiers in headache research. New York: Oxford University Press; 2004. p. 142-8.
    • (2004) Preventive Pharmacotherapy of Headaches Disorders. Frontiers in Headache Research , pp. 142-148
    • Schwaag, S.1    Rahmann, A.2    Frese, A.3    Husstedt, I.-W.4    Vollmer-Haase, J.5    Evers, S.6
  • 48
    • 0347123546 scopus 로고    scopus 로고
    • Botulinum toxin type A (Botox) in the treatment of migraine and other headaches
    • Troost BT. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Revisions Neurotherapeutics 2004; 4: 27-31.
    • (2004) Expert Revisions Neurotherapeutics , vol.4 , pp. 27-31
    • Troost, B.T.1
  • 49
    • 0038211994 scopus 로고    scopus 로고
    • 'Disease modification' in chronic migraine with botulinum toxin type A: Long-term experience
    • Mathew N, Kallasam J, Kaupp A, Meadors L. 'Disease modification' in chronic migraine with botulinum toxin type A: long-term experience. Headache 2002; 42: 454.
    • (2002) Headache , vol.42 , pp. 454
    • Mathew, N.1    Kallasam, J.2    Kaupp, A.3    Meadors, L.4
  • 50
    • 0036834143 scopus 로고    scopus 로고
    • Treatment of headache with botulinum toxin A: A review according to evidence-based medicine criteria
    • Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A: a review according to evidence-based medicine criteria. Cephalalgia 2002; 22: 699-710.
    • (2002) Cephalalgia , vol.22 , pp. 699-710
    • Evers, S.1    Rahmann, A.2    Vollmer-Haase, J.3    Husstedt, I.W.4
  • 51
    • 0038167467 scopus 로고    scopus 로고
    • Is there a role for botulinum toxin in the treatment of migraine?
    • Evers S. Is there a role for botulinum toxin in the treatment of migraine? Curr Pain Headache Rep 2003; 7: 229-34.
    • (2003) Curr Pain Headache Rep , vol.7 , pp. 229-234
    • Evers, S.1
  • 52
    • 0042232391 scopus 로고    scopus 로고
    • Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins
    • Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43 (Suppl 1): S16-24.
    • (2003) Headache , vol.43 , Issue.SUPPL. 1
    • Dolly, O.1
  • 53
    • 0042232400 scopus 로고    scopus 로고
    • Evidence for antinociceptive activity of botulinum toxin type A in pain management
    • Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 (Suppl 1): S9-15.
    • (2003) Headache , vol.43 , Issue.SUPPL. 1
    • Aoki, K.R.1
  • 54
    • 1642568305 scopus 로고    scopus 로고
    • Regulation of calcitonin-gene related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy
    • Durham PL, Cady R, Cady R. Regulation of calcitonin-gene related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44: 35-43.
    • (2004) Headache , vol.44 , pp. 35-43
    • Durham, P.L.1    Cady, R.2    Cady, R.3
  • 55
    • 0035656457 scopus 로고    scopus 로고
    • Botulinum toxin type A and EMG: A key to the understanding of chronic tension-type headaches?
    • Rollnik JD, Karst M, Fink M, Dengler R. Botulinum toxin type A and EMG: a key to the understanding of chronic tension-type headaches? Headache 2001; 41: 985-9.
    • (2001) Headache , vol.41 , pp. 985-989
    • Rollnik, J.D.1    Karst, M.2    Fink, M.3    Dengler, R.4
  • 56
    • 0037322405 scopus 로고    scopus 로고
    • Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin
    • Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein H. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003; 250: 188-93.
    • (2003) J Neurol , vol.250 , pp. 188-193
    • Kramer, H.H.1    Angerer, C.2    Erbguth, F.3    Schmelz, M.4    Birklein, H.5
  • 57
    • 4744343159 scopus 로고    scopus 로고
    • The trigeminal complex and migraine: Current concepts and synthesis
    • Bartsch T, Goadsby PJ. The trigeminal complex and migraine: current concepts and synthesis. Curr Pain Headache Rep 2003; 2: 149-54.
    • (2003) Curr Pain Headache Rep , vol.2 , pp. 149-154
    • Bartsch, T.1    Goadsby, P.J.2
  • 59
    • 0025908846 scopus 로고
    • Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofacial inputs
    • Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofacial inputs. Pain 1991; 46: 125-32.
    • (1991) Pain , vol.46 , pp. 125-132
    • Olesen, J.1
  • 60
    • 0036782213 scopus 로고    scopus 로고
    • Botulinum toxin therapy for myofascial pain disorders
    • Lang AM. Botulinum toxin therapy for myofascial pain disorders. Curr Pain Headache Rep 2002; 6: 355-60.
    • (2002) Curr Pain Headache Rep , vol.6 , pp. 355-360
    • Lang, A.M.1
  • 61
    • 0035076007 scopus 로고    scopus 로고
    • Pharmacology and immunology of botolinum toxin serotypes
    • Aoki KR. Pharmacology and immunology of botolinum toxin serotypes. J Neurol 2001; 248 (Suppl 1): 13-10.
    • (2001) J Neurol , vol.248 , Issue.SUPPL. 1 , pp. 13-10
    • Aoki, K.R.1
  • 63
    • 4744346674 scopus 로고    scopus 로고
    • Managing patients with botulinum toxin antibodies
    • Brin MF, Hallet M, Jankovic J, eds. Philadelphia: Lippincott Williams & Wilkins
    • Dressler D. Managing patients with botulinum toxin antibodies. In Brin MF, Hallet M, Jankovic J, eds. Scientific therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 417-26.
    • (2002) Scientific Therapeutic Aspects of Botulinum Toxin , pp. 417-426
    • Dressler, D.1
  • 64
    • 0023227635 scopus 로고
    • Amynoglycosides and 3,4 diaminopyridine on neuromuscular block caused by botulinum type A toxin
    • Molgio J, Lemeignan M, Thesleff S. Amynoglycosides and 3,4 diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987; 10: 464-70.
    • (1987) Muscle Nerve , vol.10 , pp. 464-470
    • Molgio, J.1    Lemeignan, M.2    Thesleff, S.3
  • 65
    • 0011111710 scopus 로고    scopus 로고
    • Botulinum toxin type A Botox for pain and headache
    • Brin MF, Hallet M, Jankovic J, eds. Philadelphia: Lippincott Williams and Wilkins
    • Brin MF, Binder W, Blitzer A, Schenrock L, Pogoda JM. Botulinum toxin type A Botox for pain and headache. In Brin MF, Hallet M, Jankovic J, eds. Scientific therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 233-50.
    • (2002) Scientific Therapeutic Aspects of Botulinum Toxin , pp. 233-250
    • Brin, M.F.1    Binder, W.2    Blitzer, A.3    Schenrock, L.4    Pogoda, J.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.